Peer-reviewed veterinary case report
Lantharenol phosphate binder tested for safety and effect in adult
By Schmidt, Bernard H et al.·Published in BMC veterinary research·2012·Bayer Animal Health GmbH, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Tolerability and efficacy of the intestinal phosphate binder Lantharenol® in cats.
- Species:
- cat
Plain-English summary
A group of healthy adult cats was given a new intestinal phosphate binder called Lantharenol to see how well it worked and if they could tolerate it. The cats were fed a regular diet while the researchers gradually increased the dose of Lantharenol to find the maximum amount they could handle without side effects. The study found that the cats tolerated the treatment well, and it helped shift phosphorus excretion from urine to feces, which can be beneficial for cats with kidney disease. Overall, Lantharenol appears to be a safe and effective option for managing phosphorus levels in cats.
People also search for: cat kidney disease treatment · Lantharenol for cats · phosphorus binder for cats · cat diet for kidney disease
Abstract
BACKGROUND: Tolerability and efficacy of the intestinal phosphate binder Lantharenol® (lanthanum carbonate octahydrate) were tested in two prospective, randomized and negative controlled laboratory studies with healthy adult cats fed commercial maintenance diets non-restricted in phosphorus. In the first study, the maximal tolerated dose was determined. Starting from a dose of 0.125 g/kg body weight mixed with the daily feed ration, the dose of Lantharenol® was doubled every other week until signs of intolerability were observed (N=10 cats compared to 5 untreated controls). In the second study, the effects of feed supplementation for two weeks with approximately 2, 6, and 20% of the maximal tolerated dose on phosphorus excretion patterns and balance were assessed (N=8 cats per group). RESULTS: Lantharenol® was found to be safe and well tolerated up to the dose of 1 g/kg bodyweight, corresponding to a concentration of 84 g Lantharenol®/kg complete feed, defined as dry matter with a standard moisture content of 12%. Feed supplementation for two weeks with approximately 2-20% of this dosage (i.e., 1.6, 4.8, and 16 g/kg complete feed) resulted in a shift from urinary to faecal phosphorus excretion. Apparent phosphorus digestibility was dose-dependently reduced compared to the control group fed with diet only (N=8). CONCLUSIONS: The feed additive was well accepted and tolerated by all cats. Therefore, Lantharenol® presents a well tolerated and efficacious option to individually tailor restriction of dietary phosphorus as indicated, for instance, in feline chronic kidney disease.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22305206/